Amedeo Smart

Free Medical Literature Service



Autoimmune Disorders

  Free Subscription

Articles published in
Kidney Int
    October 2022
  1. JACKSON SW, Alpers CE
    Lupus nephritis transcriptomics across space and time.
    Kidney Int. 2022;102:694-696.
    >> Share

    September 2022
  2. DIEBOLD M, Locher E, Boide P, Enzler-Tschudy A, et al
    Incidence of new onset glomerulonephritis after SARS-CoV-2 mRNA vaccination is not increased.
    Kidney Int. 2022 Sep 9. pii: S0085-2538(22)00697.
    >> Share

  3. KURIEN AA, Jansi Prema KS, Walker P, Caza T, et al
    Traditional indigenous medicines are an etiologic consideration for NELL1-positive membranous nephropathy.
    Kidney Int. 2022 Sep 9. pii: S0085-2538(22)00712.
    >> Share

  4. LUO C, Ouyang Y, Shi S, Li G, et al
    Particulate matter of air pollution may increase risk of kidney failure in IgA nephropathy.
    Kidney Int. 2022 Sep 7. pii: S0085-2538(22)00696.
    >> Share

    August 2022
  5. TODA E, Sawada A, Takeuchi K, Wakamatsu K, et al
    Inhibition of the chemokine signal regulator FROUNT by disulfiram ameliorates crescentic glomerulonephritis.
    Kidney Int. 2022 Aug 29. pii: S0085-2538(22)00687.
    >> Share

  6. CHANG JC, Weiss PF, Xiao R, Atkinson MA, et al
    Use of renin angiotensin aldosterone system inhibitors in children with lupus and time to glucocorticoid discontinuation.
    Kidney Int. 2022;102:395-404.
    >> Share

  7. YU XJ, Wang SX
    Recognizing the true face of noninfectious cryoglobulinemic glomerulonephritis.
    Kidney Int. 2022;102:238-241.
    >> Share

    July 2022
  8. FLOEGE J, Wied S, Rauen T
    Assessing prognosis in IgA nephropathy.
    Kidney Int. 2022;102:22-24.
    >> Share

  9. PARIKH SV, Malvar A, Song H, Shapiro J, et al
    Molecular profiling of kidney compartments from serial biopsies differentiate treatment responders from non-responders in lupus nephritis.
    Kidney Int. 2022 Jul 1. pii: S0085-2538(22)00512.
    >> Share

    June 2022
  10. MISRA DP, Agarwal V
    Management of refractory lupus nephritis: rationale to consider tacrolimus.
    Kidney Int. 2022;101:1293.
    >> Share

  11. LODI L, Mastrolia MV, Bello F, Rossi GM, et al
    Type I interferon-related kidney disorders.
    Kidney Int. 2022;101:1142-1159.
    >> Share

    May 2022
  12. MONTAGUD-MARRAHI E, Cuadrado-Payan E, Hermida E, Cacho J, et al
    Preemptive simultaneous pancreas kidney transplantation has survival benefit to patient.
    Kidney Int. 2022 May 26. pii: S0085-2538(22)00385.
    >> Share

  13. JAVAUGUE V, Valeri AM, Sathick IJ, Said SM, et al
    The characteristics of seronegative and seropositive non-hepatitis-associated cryoglobulinemic glomerulonephritis.
    Kidney Int. 2022 May 2. pii: S0085-2538(22)00349.
    >> Share

    April 2022
  14. BARBOUR SJ, Coppo R, Zhang H, Liu ZH, et al
    Application of the International IgA Nephropathy Prediction Tool one or two years post-biopsy.
    Kidney Int. 2022 Apr 29. pii: S0085-2538(22)00342.
    >> Share

    March 2022
  15. VINK CH, van Cranenbroek B, van der Heijden JW, Koenen HPJM, et al
    Daratumumab for multidrug-resistant phospholipase-A2 receptor-related membranous nephropathy.
    Kidney Int. 2022;101:646-647.
    >> Share

  16. CHENG L, Gou SJ
    Whether the addition of high-dosage methylprednisolone to plasma exchange was more effective than plasma exchange in the treatment for severe antineutrophil cytoplasmic antibody-associated vasculitis?
    Kidney Int. 2022;101:647-648.
    >> Share

    February 2022
  17. KANT S, Azar A, Geetha D
    Antibody response to COVID-19 booster vaccine in rituximab-treated patients with anti-neutrophil cytoplasmic antibody-associated vasculitis.
    Kidney Int. 2022;101:414-415.
    >> Share

  18. CAZA TN, Larsen CP
    Lipoic acid in neural epidermal growth factor-like 1-associated membranous nephropathy: more than a coincidence?
    Kidney Int. 2022;101:418-419.
    >> Share

  19. STEHLE T, Grimbert P, Remy P, Moktefi A, et al
    Anti-CD38 therapy for PLA2R-positive membranous nephropathy resistant to conventional immunosuppression.
    Kidney Int. 2022;101:416-418.
    >> Share

  20. GLEESON S, Lightstone L
    BLISS-LN trial revisited: function matters.
    Kidney Int. 2022;101:224-226.
    >> Share

  21. DHAUN N, McAdoo SP
    The changing role of glucocorticoids in the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis.
    Kidney Int. 2022;101:201-204.
    >> Share

    January 2022
  22. KIM HJ, Jung M, Lim BJ, Han SH, et al
    New Onset of Class III Lupus Nephritis with Multi-Organ Involvement after COVID -19 Vaccination.
    Kidney Int. 2022 Jan 30. pii: S0085-2538(22)00064.
    >> Share

  23. LI X, Zhang X
    Comments on the 2021 Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guideline for anticoagulant therapy in patients with membranous nephropathy.
    Kidney Int. 2022;101:186-187.
    >> Share

  24. KLOMJIT N, Zand L
    Catastrophic kidney infarction.
    Kidney Int. 2022;101:189.
    >> Share

    December 2021
  25. ZAMBRANO S, He L, Kano T, Sun Y, et al
    Molecular insights into the early stage of glomerular injury in IgA nephropathy using single-cell RNA sequencing.
    Kidney Int. 2021 Dec 27. pii: S0085-2538(21)01211.
    >> Share

  26. AYOUB I, Wolf BJ, Geng L, Song H, et al
    Prediction Models of Treatment Response in Lupus Nephritis.
    Kidney Int. 2021 Dec 3. pii: S0085-2538(21)01079.
    >> Share

  27. PLAISIER E, Not A, Buob D, Ronco P, et al
    Contactin-1-associated membranous nephropathy: complete immunologic and clinical remission with rituximab.
    Kidney Int. 2021;100:1342-1344.
    >> Share

  28. MULLER R, Lebrun G
    Strawberry gingivitis.
    Kidney Int. 2021;100:1353.
    >> Share

  29. ENGHARD P, Zickler D, Sonnemann J, Schneider W, et al
    Imlifidase as novel treatment strategy in anti-neutrophil cytoplasmic antibody-induced pulmonary-renal syndrome.
    Kidney Int. 2021;100:1344-1345.
    >> Share

  30. DEBIEC H, Ronco P
    When contactin antibodies hit the podocyte: a new neurorenal syndrome.
    Kidney Int. 2021;100:1163-1165.
    >> Share

  31. GULATI K, Edwards H, Prendecki M, Cairns TD, et al
    Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis.
    Kidney Int. 2021;100:1316-1324.
    >> Share

    How cyclosporine reduces mycophenolic acid exposure by 40% while other calcineurin inhibitors do not.
    Kidney Int. 2021;100:1185-1189.
    >> Share

    November 2021
  33. KANT S, Geetha D
    Impact of rituximab on humoral response to COVID-19 booster vaccine and antibody kinetics in patients with anti-neutrophil cytoplasmic antibody vasculitis.
    Kidney Int. 2021;100:1124-1127.
    >> Share

  34. HENDRA H, Mahalingasivam V, Salama AD, Burns A, et al
    The Case | Unexplained inflammation after treatment for granulomatosis with polyangiitis.
    Kidney Int. 2021;100:1147-1148.
    >> Share

    October 2021
  35. CAMBIER A, Gleeson PJ, Abbad L, Canesi F, et al
    Kidney Int. 2021 Oct 28. pii: S0085-2538(21)00954.
    >> Share

  36. SPAIN RI, Andeen NK, Gibson PC, Samuels M, et al
    Lipoic acid supplementation associated with neural epidermal growth factor-like 1 (NELL1)-associated membranous nephropathy.
    Kidney Int. 2021 Oct 16. pii: S0085-2538(21)00946.
    >> Share

  37. MEJIA-VILET JM, Malvar A, Arazi A, Rovin BH, et al
    The Lupus Nephritis Management Renaissance.
    Kidney Int. 2021 Oct 4. pii: S0085-2538(21)00874.
    >> Share

  38. VILLA M, Diaz-Crespo F, Perez de Jose A, Verdalles U, et al
    A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-CoV-2 vaccination: casualty or causality?
    Kidney Int. 2021;100:937-938.
    >> Share

  39. LE QUINTREC M, Teisseyre M, Bec N, Delmont E, et al
    Contactin-1 is a novel target antigen in membranous nephropathy associated with chronic inflammatory demyelinating polyneuropathy.
    Kidney Int. 2021 Oct 1. pii: S0085-2538(21)00806.
    >> Share

  40. ROVIN BH, Adler SG, Barratt J, Bridoux F, et al
    Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases.
    Kidney Int. 2021;100:753-779.
    >> Share

  41. ROCCATELLO D, Sciascia S
    A toggle switch linking coagulation and innate immunity in antiphospholipid antibody syndrome.
    Kidney Int. 2021;100:740-742.
    >> Share

    September 2021
  42. ZAVALA-MIRANDA MF, Gonzalez-Ibarra SG, Perez-Arias AA, Uribe-Uribe NO, et al
    New onset systemic lupus erythematosus opening as class V lupus nephritis after COVID-19 vaccination.
    Kidney Int. 2021 Sep 21. pii: S0085-2538(21)00869.
    >> Share

  43. ROVIN BH, Furie R, Teng YKO, Contreras G, et al
    A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis.
    Kidney Int. 2021 Sep 21. pii: S0085-2538(21)00862.
    >> Share

  44. HUERTA A, Caballero Bermejo AF, de Villa LF, Sedano R, et al
    Measurement of the passage of mycophenolic acid into breast milk in a patient with lupus nephritis.
    Kidney Int. 2021;100:711.
    >> Share

  45. SALHI S, Ribes D, Colombat M, Fortenfant F, et al
    Bortezomib plus dexamethasone for rituximab-resistant PLA2R(+) membranous nephropathy.
    Kidney Int. 2021;100:708-709.
    >> Share

  46. BORZA DB
    Fumarate in membranous nephropathy: more questions than answers.
    Kidney Int. 2021;100:707.
    >> Share

    August 2021
  47. GUEGUEN L, Loheac C, Saidani N, Khatchatourian L, et al
    Membranous nephropathy following anti-Covid-19 mRNA vaccination.
    Kidney Int. 2021 Aug 19. pii: S0085-2538(21)00757.
    >> Share

  48. TUSCHEN K, Brasen JH, Schmitz J, Vischedyk M, et al
    Relapse of Class V Lupus Nephritis after Vaccination with COVID-19 mRNA Vaccine.
    Kidney Int. 2021 Aug 2. pii: S0085-2538(21)00738.
    >> Share

  49. PLASSE R, Nee R, Gao S, Olson S, et al
    AKI with Gross Hematuria and IgA Nephropathy after COVID Vaccine.
    Kidney Int. 2021 Aug 2. pii: S0085-2538(21)00739.
    >> Share

    July 2021
  50. DA Y, Goh GH, Khatri P
    A Case of Membranous Nephropathy Following Pfizer-BioNTech mRNA vaccine against Coronavirus 2019.
    Kidney Int. 2021 Jul 29. pii: S0085-2538(21)00735.
    >> Share

  51. HANNA C, Herrera Hernandez LP, Bu L, Kizilbash S, et al
    IgA Nephropathy presenting as macroscopic hematuria in 2 pediatric patients after receiving the Pfizer COVID-19 vaccine.
    Kidney Int. 2021 Jul 5. pii: S0085-2538(21)00666.
    >> Share

  52. RABANT M, Dessaix K, Buob D, Fagniez O, et al
    The Case | Membranous nephropathy after alemtuzumab treatment.
    Kidney Int. 2021;100:249-250.
    >> Share

  53. BERCHTOLD L, Letouze E, Alexander MP, Canaud G, et al
    Corrigendum to Berchtold L, Letouze E, Alexander MP, et al. HLA-D and PLA2R1 risk alleles associate with recurrent primary membranous nephropathy in kidney transplant recipients. Kidney Int. 2021;99:671-685.
    Kidney Int. 2021;100:243.
    >> Share

    June 2021
  54. KUDOSE S, Friedman P, Albajrami O, D'Agati VD, et al
    Histologic correlates of gross hematuria following Moderna COVID-19 vaccine in patients with IgA nephropathy.
    Kidney Int. 2021 Jun 17. pii: S0085-2538(21)00598.
    >> Share

  55. PERRIN P, Bassand X, Benotmane I, Bouvier N, et al
    Gross hematuria following SARS-CoV-2 vaccination in patients with IgA nephropathy.
    Kidney Int. 2021 Jun 1. pii: S0085-2538(21)00564.
    >> Share

  56. NANGAKU M, Fogo AB
    Does a preclinical randomized controlled trial, pRCT, resolve the gap between animal studies and human trials?
    Kidney Int. 2021;99:1262-1264.
    >> Share

    May 2021
  57. SEKAR A, Campbell R, Tabbara J, Rastogi P, et al
    ANCA glomerulonephritis post Moderna COVID-19 vaccination.
    Kidney Int. 2021 May 31. pii: S0085-2538(21)00555.
    >> Share

  58. TAN HZ, Tan RY, Jun Choo JC, Lim CC, et al
    Is COVID-19 Vaccination unmasking Glomerulonephritis?
    Kidney Int. 2021 May 22. pii: S0085-2538(21)00504.
    >> Share

  59. AYDIN MF, Yildiz A, Oruc A, Sezen M, et al
    Relapse of Primary Membranous Nephropathy after inactivated SARS-CoV-2 Virus Vaccination.
    Kidney Int. 2021 May 13. pii: S0085-2538(21)00494.
    >> Share

  60. KANO T, Suzuki H, Makita Y, Fukao Y, et al
    Nasal-associated lymphoid tissue is the major induction site for nephritogenic IgA in murine IgA nephropathy.
    Kidney Int. 2021 May 4. pii: S0085-2538(21)00467.
    >> Share

  61. CHAPMAN FA, Dhaun N
    STARMEN: progress in membranous nephropathy?
    Kidney Int. 2021;99:1242-1243.
    >> Share

    An impending obituary for the primacy of P values in glomerulonephritis trial results?
    Kidney Int. 2021;99:1241-1242.
    >> Share

  63. FERNANDEZ-JUAREZ G, Rojas-Rivera J, Praga M
    The authors reply.
    Kidney Int. 2021;99:1243.
    >> Share

  64. ANDERS HJ, Lei Y, Rovin BH
    The authors reply.
    Kidney Int. 2021;99:1242.
    >> Share

    April 2021
  65. GUL RAHIM SE, Lin J, Wang JC
    A case of gross hematuria and IgA Nephropathy Flare up following SARS-CoV-2 vaccination.
    Kidney Int. 2021 Apr 28. pii: S0085-2538(21)00465.
    >> Share

  66. WHEELER DC, Toto RD, Stefansson BV, Jongs N, et al
    A pre-specified analysis of the DAPA-CKD trial indicates effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy.
    Kidney Int. 2021 Apr 17. pii: S0085-2538(21)00396.
    >> Share

  67. BARRATT J, Floege J
    SGLT-2 inhibition in IgA nephropathy: the new standard-of-care?
    Kidney Int. 2021 Apr 17. pii: S0085-2538(21)00385.
    >> Share

  68. LERNER GB, Virmani S, Henderson JM, Francis JM, et al
    A conceptual framework linking immunology, pathology, and clinical features in primary membranous nephropathy.
    Kidney Int. 2021 Apr 12. pii: S0085-2538(21)00377.
    >> Share

  69. SANTORIELLO D, Bomback AS, Kudose S, Batal I, et al
    Anti-neutrophil cytoplasmic antibody associated glomerulonephritis complicating treatment with hydralazine.
    Kidney Int. 2021 Apr 12. pii: S0085-2538(21)00379.
    >> Share

  70. FLOEGE J, Rovin BH
    The STARMEN trial: rethinking calcineurin inhibitor therapy in membranous nephropathy.
    Kidney Int. 2021;99:811-813.
    >> Share

  71. DELAFOSSE M, Ponlot E, Esteve E, Ghislain L, et al
    Personalized phospholipase A2 receptor antibody-driven rituximab treatment strategy in membranous nephropathy.
    Kidney Int. 2021;99:1023-1024.
    >> Share

  72. FERNANDEZ-JUAREZ G, Rojas-Rivera J, Praga M
    The authors reply.
    Kidney Int. 2021;99:1024-1025.
    >> Share

    March 2021
  73. ARTINGER K, Kirsch AH, Mooslechner AA, Cooper DJ, et al
    Blockade of tumor necrosis factor superfamily members CD30 and OX40 abrogates disease activity in murine immune-mediated glomerulonephritis.
    Kidney Int. 2021 Mar 27. pii: S0085-2538(21)00345.
    >> Share

    Complement in membranous nephropathy: what we thought we knew and what we really know.
    Kidney Int. 2021 Mar 24. pii: S0085-2538(21)00297.
    >> Share

  75. NEGREA L, Rovin BH
    Gross Hematuria Following Vaccination for SARS-CoV2 in Two Patients with IgA Nephropathy.
    Kidney Int. 2021 Mar 23. pii: S0085-2538(21)00286.
    >> Share

  76. ROBSON KJ, Kitching AR
    Recurrent membranous nephropathy after transplantation: donor antigen and HLA converge in defining risk.
    Kidney Int. 2021;99:545-548.
    >> Share

  77. FARRAH TE, Dhaun N
    Antineutrophil cytoplasm antibody positivity, kidney impairment, and cholesterol embolization.
    Kidney Int. 2021;99:774.
    >> Share

    February 2021
  78. LEI Y, Sehnert B, Voll RE, Jacobs-Cacha C, et al
    A multicenter blinded preclinical randomized controlled trial on Jak1/2 inhibition in MRL/MpJ-Fas(lpr) mice with proliferative lupus nephritis predicts low effect size.
    Kidney Int. 2021 Feb 16. pii: S0085-2538(21)00205.
    >> Share

    Are new treatments for lupus nephritis on the horizon?
    Kidney Int. 2021;99:298-300.
    >> Share

  80. ANDERS HJ, Lei Y, Rovin BH
    Induction and maintenance therapy of lupus nephritis: an obituary.
    Kidney Int. 2021;99:288-291.
    >> Share

    Improving medication adherence in patients with lupus nephritis.
    Kidney Int. 2021;99:285-287.
    >> Share

    January 2021
  82. PAWLUCZYK IZ, Didangelos A, Barbour SJ, Er L, et al
    Differential expression of microRNA miR-150-5p in IgA nephropathy as a potential mediator and marker of disease progression.
    Kidney Int. 2021 Jan 5. pii: S0085-2538(20)31553.
    >> Share

  83. FLOEGE J, Johnson RJ
    Hyperuricemia and progression of chronic kidney disease: to treat or not to treat?
    Kidney Int. 2021;99:14-16.
    >> Share

  84. RONCO P, Rovin B, Nangaku M, Wyatt C, et al
    Milestones in nephrology and welcoming the future: the 61st anniversary of the International Society of Nephrology.
    Kidney Int. 2021;99:2-4.
    >> Share

  85. KUDOSE S, Santoriello D, Debiec H, Canetta PA, et al
    The clinicopathologic spectrum of segmental membranous glomerulopathy.
    Kidney Int. 2021;99:247-255.
    >> Share

    December 2020
  86. PERKINS GB, Kim J, Coates PT
    Going Rogue: how autoantibodies become pathogenic.
    Kidney Int. 2020 Dec 18. pii: S0085-2538(20)31522.
    >> Share

    November 2020
  87. BARBOUR SJ, Coppo R, Er L, Russo ML, et al
    Updating the International IgA Nephropathy Prediction Tool for use in children.
    Kidney Int. 2020 Nov 18. pii: S0085-2538(20)31385.
    >> Share

  88. FERNANDEZ-JUAREZ G, Rojas-Rivera J, Logt AV, Justino J, et al
    The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy.
    Kidney Int. 2020 Nov 6. pii: S0085-2538(20)31251.
    >> Share

  89. HAYASHI N, Beck LH Jr
    Moore's law for membranous nephropathy.
    Kidney Int. 2020;98:1081-1084.
    >> Share

  90. TURNER MP, Storey BC, Mittal S, Macanovic J, et al
    Candida crescents in a renal allograft.
    Kidney Int. 2020;98:1356.
    >> Share

    October 2020
  91. CAZA T, Hassen S, Kuperman M, Sharma S, et al
    Neural cell adhesion molecule 1 is a novel autoantigen in membranous lupus nephritis.
    Kidney Int. 2020 Oct 9. pii: S0085-2538(20)31180.
    >> Share

  92. CHEUNG CK, Barratt J
    Should we STOP immunosuppression for IgA nephropathy? Long-term outcomes from the STOP-IgAN trial.
    Kidney Int. 2020;98:836-838.
    >> Share

  93. ODLER B, Flick H, Pollheimer MJ, Goritschan A, et al
    The Case | Glomerulonephritis in a patient with rheumatoid arthritis.
    Kidney Int. 2020;98:1057-1058.
    >> Share

    September 2020
  94. PRENDECKI M, Clarke C, Cairns T, Cook T, et al
    Anti-glomerular basement membrane disease during the COVID-19 pandemic.
    Kidney Int. 2020;98:780-781.
    >> Share

  95. BERCHTOLD L, Letouze E, Alexander MP, Canaud G, et al
    HLA-D and PLA2R1 risk alleles associate with recurrent primary membranous nephropathy in kidney transplant recipients.
    Kidney Int. 2020 Sep 1. pii: S0085-2538(20)30967.
    >> Share

  96. SCHENA FP, Anelli VW, Trotta J, Di Noia T, et al
    Development and testing of an artificial intelligence tool for predicting end stage kidney disease in patients with immunoglobulin A nephropathy.
    Kidney Int. 2020 Sep 1. pii: S0085-2538(20)30969.
    >> Share

    August 2020
  97. CAZA T, Hassen S, Dvanajscak Z, Kuperman M, et al
    NELL1 is a target antigen in malignancy-associated membranous nephropathy.
    Kidney Int. 2020 Aug 20. pii: S0085-2538(20)30956.
    >> Share

    July 2020
  98. IHARA K, Skupien J, Krolewski B, Md Dom ZI, et al
    A profile of multiple circulating tumor necrosis factor receptors associated with early progressive kidney decline in Type 1 Diabetes is similar to profiles in autoimmune disorders.
    Kidney Int. 2020 Jul 24. pii: S0085-2538(20)30834.
    >> Share

  99. JO HA, Hyeon JS, Yang SH, Jung Y, et al
    Fumarate modulates phospholipase A2 receptor autoimmunity-induced podocyte injury in membranous nephropathy.
    Kidney Int. 2020 Jul 23. pii: S0085-2538(20)30825.
    >> Share

    June 2020
  100. KURATA Y, Tanaka T, Nangaku M
    The role of hypoxia in the pathogenesis of lupus nephritis.
    Kidney Int. 2020 Jun 26. pii: S0085-2538(20)30702.
    >> Share

  101. ABDIRAMA D, Tesch S, Griessbach AS, von Spee-Mayer C, et al
    Nuclear antigen-reactive CD4(+) T cells expand in active systemic lupus erythematosus, produce effector cytokines, and invade the kidneys.
    Kidney Int. 2020 Jun 24. pii: S0085-2538(20)30704.
    >> Share

  102. SETHI S, Debiec H, Madden B, Vivarelli M, et al
    Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients.
    Kidney Int. 2020 Jun 10. pii: S0085-2538(20)30640.
    >> Share

    May 2020
  103. BARBOUR SJ, Canney M, Coppo R, Zhang H, et al
    Improving treatment decisions using personalized risk assessment from the International IgA Nephropathy Prediction Tool.
    Kidney Int. 2020 May 25. pii: S0085-2538(20)30544.
    >> Share

  104. RAUEN T, Wied S, Fitzner C, Eitner F, et al
    After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy.
    Kidney Int. 2020 May 22. pii: S0085-2538(20)30549.
    >> Share

  105. JONES BE, Herrera CA, Agosto-Burgos C, Starmer J, et al
    ANCA autoantigen gene expression highlights neutrophil heterogeneity where expression in normal-density neutrophils correlates with ANCA-induced activation.
    Kidney Int. 2020 May 21. pii: S0085-2538(20)30538.
    >> Share

  106. COUSER WG
    The pathogenesis of human membranous nephropathy: we are (almost) there.
    Kidney Int. 2020;97:849-852.
    >> Share

    April 2020
  107. YANG SR, Hua KF, Chu LJ, Hwu YK, et al
    Xenon blunts NF-kappaB/NLRP3 inflammasome activation and improves acute onset of accelerated and severe lupus nephritis in mice.
    Kidney Int. 2020 Apr 6. pii: S0085-2538(20)30357.
    >> Share

  108. MALVAR A, Rovin BH
    The authors reply.
    Kidney Int. 2020;97:807.
    >> Share

  109. VAN BOMMEL EJM, Lytvyn Y, Perkins BA, Soleymanlou N, et al
    Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function.
    Kidney Int. 2020;97:631-635.
    >> Share

    March 2020
  110. SAID SM, Leung N, Alexander MP, Cornell LD, et al
    DNAJB9-positive monotypic fibrillary glomerulonephritis is not associated with monoclonal gammopathy in the vast majority of patients.
    Kidney Int. 2020 Mar 28. pii: S0085-2538(20)30267.
    >> Share

    February 2020
  111. SCINDIA Y, Wlazlo E, Ghias E, Cechova S, et al
    Modulation of iron homeostasis with hepcidin ameliorates spontaneous murine lupus nephritis.
    Kidney Int. 2020 Feb 17. pii: S0085-2538(20)30139.
    >> Share

  112. TSOKOS GC
    Notch notches lupus.
    Kidney Int. 2020;97:251-253.
    >> Share

  113. SUGAHARA M, Tanaka T, Nangaku M
    Modulating the immune system to delay the clinical onset of type 1 diabetes.
    Kidney Int. 2020;97:248-250.
    >> Share

    January 2020
  114. CRICKX E, Weill JC, Reynaud CA, Mahevas M, et al
    Anti-CD20-mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives.
    Kidney Int. 2020 Jan 30. pii: S0085-2538(20)30108.
    >> Share

    September 2019
    Said the glucose sensor to the insulin pump: can glycemic control be improved in hospitalized ESRD patients with diabetes mellitus?
    Kidney Int. 2019;96:540-542.
    >> Share

    May 2019
  116. KODAMA Y, Hyodo F, Yamato M, Yasukawa K, et al
    Dynamic nuclear polarization magnetic resonance imaging and the oxygen-sensitive paramagnetic agent OX63 provide a noninvasive quantitative evaluation of kidney hypoxia in diabetic mice.
    Kidney Int. 2019 May 24. pii: S0085-2538(19)30515.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016